hMAO-B-IN-6 (Compound 17d) is a potent and selective hMAO-B inhibitor with an IC50 of 67.02 nM. It has demonstrated efficacy in preclinical Alzheimer's disease research, where it reversed scopolamine-induced cognitive deficits in mouse models, supporting its investigation for neurodegenerative disorders.